Financial Ratios Jointown Pharmaceutical Group Co., Ltd
Equities
600998
CNE100000W45
Pharmaceuticals
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.440 CNY | -0.18% |
|
+1.68% | +6.25% |
Jun. 06 | Jointown Pharmaceutical Gets Drug Registration for Betamethasone Sodium Phosphate Injection | MT |
May. 19 | Jointown to Invest 23 Million Yuan Into Pharma-Focused Investment Fund | MT |
Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 3.06 | 2.31 | 2.49 | 2.93 | 2.51 | |||||
Return on Total Capital | 5.84 | 4.4 | 5.01 | 6.15 | 5.39 | |||||
Return On Equity % | 14.23 | 9.9 | 8.2 | 7.87 | 8.84 | |||||
Return on Common Equity | 15.93 | 11.86 | 9.46 | 9.32 | 9.79 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 8.91 | 7.98 | 7.74 | 7.99 | 7.73 | |||||
SG&A Margin | 5.11 | 4.98 | 4.73 | 4.79 | 4.76 | |||||
EBITDA Margin % | 3.79 | 2.95 | 2.96 | 3.31 | 3.04 | |||||
EBITA Margin % | 3.41 | 2.57 | 2.57 | 2.93 | 2.63 | |||||
EBIT Margin % | 3.36 | 2.52 | 2.52 | 2.89 | 2.58 | |||||
Income From Continuing Operations Margin % | 3.05 | 2.13 | 1.63 | 1.52 | 1.84 | |||||
Net Income Margin % | 2.77 | 2 | 1.48 | 1.45 | 1.65 | |||||
Net Avail. For Common Margin % | 2.77 | 2 | 1.48 | 1.45 | 1.65 | |||||
Normalized Net Income Margin | 1.31 | 0.93 | 1 | 1.21 | 1.44 | |||||
Levered Free Cash Flow Margin | -0.78 | 2.24 | 2.02 | 0.98 | 0.92 | |||||
Unlevered Free Cash Flow Margin | -0.2 | 2.83 | 2.56 | 1.53 | 1.45 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 1.46 | 1.47 | 1.58 | 1.62 | 1.56 | |||||
Fixed Assets Turnover | 15.93 | 15.36 | 16.36 | 17.05 | 16.92 | |||||
Receivables Turnover (Average Receivables) | 4.29 | 4.41 | 4.78 | 5.01 | 4.97 | |||||
Inventory Turnover (Average Inventory) | 7 | 7.44 | 7.92 | 7.4 | 6.52 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.29 | 1.28 | 1.27 | 1.26 | 1.27 | |||||
Quick Ratio | 0.92 | 0.9 | 0.85 | 0.82 | 0.81 | |||||
Operating Cash Flow to Current Liabilities | 0.07 | 0.06 | 0.07 | 0.08 | 0.05 | |||||
Days Sales Outstanding (Average Receivables) | 85.39 | 82.77 | 76.41 | 72.87 | 73.59 | |||||
Days Outstanding Inventory (Average Inventory) | 52.28 | 49.08 | 46.1 | 49.31 | 56.13 | |||||
Average Days Payable Outstanding | 106.39 | 105.04 | 102.13 | 102.73 | 110.98 | |||||
Cash Conversion Cycle (Average Days) | 31.28 | 26.81 | 20.39 | 19.45 | 18.74 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 68.68 | 64.52 | 52.85 | 50.03 | 39.33 | |||||
Total Debt / Total Capital | 40.72 | 39.22 | 34.58 | 33.35 | 28.23 | |||||
LT Debt/Equity | 12.51 | 9.45 | 11.07 | 8.51 | 5.11 | |||||
Long-Term Debt / Total Capital | 7.42 | 5.75 | 7.24 | 5.67 | 3.67 | |||||
Total Liabilities / Total Assets | 68.31 | 68.5 | 68.91 | 68.23 | 67.19 | |||||
EBIT / Interest Expense | 3.62 | 2.7 | 2.9 | 3.29 | 3.05 | |||||
EBITDA / Interest Expense | 4.09 | 3.25 | 3.49 | 3.85 | 3.68 | |||||
(EBITDA - Capex) / Interest Expense | 2.67 | 2.04 | 2.48 | 3.05 | 2.92 | |||||
Total Debt / EBITDA | 4.19 | 4.69 | 3.55 | 2.91 | 2.79 | |||||
Net Debt / EBITDA | 0.63 | -0.3 | -0.57 | -0.47 | -1.09 | |||||
Total Debt / (EBITDA - Capex) | 6.41 | 7.48 | 5.01 | 3.67 | 3.52 | |||||
Net Debt / (EBITDA - Capex) | 0.97 | -0.48 | -0.8 | -0.59 | -1.38 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 11.42 | 10.42 | 14.72 | 6.92 | 1.11 | |||||
Gross Profit, 1 Yr. Growth % | 13.94 | -1.09 | 11.18 | 10.46 | -2.21 | |||||
EBITDA, 1 Yr. Growth % | 12.88 | -14.79 | 14.41 | 12.56 | -2.49 | |||||
EBITA, 1 Yr. Growth % | 13.68 | -17.56 | 13.33 | 13.2 | -3.77 | |||||
EBIT, 1 Yr. Growth % | 15.53 | -17.1 | 14.82 | 14.41 | -3.22 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 90.01 | -22.94 | -12.38 | 0.18 | 21.7 | |||||
Net Income, 1 Yr. Growth % | 78.1 | -20.38 | -14.84 | 4.27 | 15.33 | |||||
Normalized Net Income, 1 Yr. Growth % | 15.28 | -21.84 | 21.73 | 19.3 | 38.37 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 84.5 | -18.06 | -15.76 | 7.87 | 16.28 | |||||
Accounts Receivable, 1 Yr. Growth % | 11.51 | 3.5 | 8.1 | -3.72 | 7.67 | |||||
Inventory, 1 Yr. Growth % | 5 | 5.02 | 10.93 | 16.85 | 13.61 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 13.96 | 14.95 | 1.48 | 3.65 | 0.17 | |||||
Total Assets, 1 Yr. Growth % | 13.6 | 6.32 | 7.37 | 0.52 | 10.35 | |||||
Tangible Book Value, 1 Yr. Growth % | 5.05 | 9.49 | 7.14 | 6.74 | 14.08 | |||||
Common Equity, 1 Yr. Growth % | 5.81 | 7.97 | 5.75 | 5.85 | 13.59 | |||||
Cash From Operations, 1 Yr. Growth % | 24.42 | 0.44 | 15.24 | 19.1 | -35.07 | |||||
Capital Expenditures, 1 Yr. Growth % | 22.22 | -4.86 | -10.3 | -15.65 | -7 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -139.74 | -441.95 | 3.92 | -50.49 | 7.99 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -107.42 | -2.26K | 4.49 | -38.53 | 3.89 | |||||
Dividend Per Share, 1 Yr. Growth % | - | -39.99 | 66.64 | 4.31 | 3.2 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 12.79 | 10.92 | 12.55 | 10.75 | 3.98 | |||||
Gross Profit, 2 Yr. CAGR % | 14.87 | 6.16 | 4.87 | 10.82 | 3.93 | |||||
EBITDA, 2 Yr. CAGR % | 19.6 | -1.47 | -0.95 | 16.95 | 2.2 | |||||
EBITA, 2 Yr. CAGR % | 20.88 | -2.71 | -2.81 | 17.6 | 1.33 | |||||
EBIT, 2 Yr. CAGR % | 21.25 | -2.14 | -2.44 | 18.51 | 1.74 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 56.54 | 21 | -17.83 | -6.31 | 10.42 | |||||
Net Income, 2 Yr. CAGR % | 51.45 | 19.08 | -17.66 | -5.77 | 9.66 | |||||
Normalized Net Income, 2 Yr. CAGR % | 18.69 | -5.08 | -2.05 | 25.82 | 19.93 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 46.71 | 22.96 | -16.92 | -4.95 | 12.47 | |||||
Accounts Receivable, 2 Yr. CAGR % | 11.08 | 7.45 | 5.78 | 2.02 | 1.81 | |||||
Inventory, 2 Yr. CAGR % | 3.13 | 5.01 | 7.94 | 13.85 | 15.22 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 10.89 | 14.45 | 8.01 | 2.56 | 1.89 | |||||
Total Assets, 2 Yr. CAGR % | 10.1 | 9.9 | 6.85 | 3.91 | 5.32 | |||||
Tangible Book Value, 2 Yr. CAGR % | -0.08 | 7.25 | 8.31 | 6.94 | 10.35 | |||||
Common Equity, 2 Yr. CAGR % | 3.66 | 6.89 | 6.85 | 5.8 | 9.65 | |||||
Cash From Operations, 2 Yr. CAGR % | 67.87 | 11.79 | 7.59 | 17.16 | -12.06 | |||||
Capital Expenditures, 2 Yr. CAGR % | -10.4 | 7.83 | -7.62 | -13.02 | -11.43 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -35.48 | 12.59 | 88.01 | -26.7 | -31.43 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -62.01 | 8.48 | 374.11 | -18.47 | -23.23 | |||||
Dividend Per Share, 2 Yr. CAGR % | 123.49 | - | 0 | 31.84 | 3.75 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 14.45 | 12 | 12.17 | 10.64 | 7.44 | |||||
Gross Profit, 3 Yr. CAGR % | 16.74 | 9.29 | 7.81 | 6.7 | 6.29 | |||||
EBITDA, 3 Yr. CAGR % | 20.23 | 7.14 | 3.78 | 5.45 | 8.27 | |||||
EBITA, 3 Yr. CAGR % | 21.52 | 6.76 | 2.74 | 4.85 | 7.85 | |||||
EBIT, 3 Yr. CAGR % | 21.72 | 6.81 | 3.22 | 5.2 | 8.31 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 31.97 | 23.6 | 8.66 | -12.22 | 2.23 | |||||
Net Income, 3 Yr. CAGR % | 28.61 | 22.23 | 6.49 | -10.91 | 0.8 | |||||
Normalized Net Income, 3 Yr. CAGR % | 19.73 | 3.26 | 3.42 | 7.66 | 24.04 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 22.17 | 20.82 | 8.39 | -9.54 | 1.94 | |||||
Accounts Receivable, 3 Yr. CAGR % | 20 | 8.5 | 7.66 | 2.51 | 3.87 | |||||
Inventory, 3 Yr. CAGR % | 6.64 | 3.76 | 6.95 | 10.83 | 13.77 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 11.9 | 12.23 | 9.95 | 6.53 | 1.76 | |||||
Total Assets, 3 Yr. CAGR % | 15.8 | 8.83 | 9.05 | 4.71 | 6.02 | |||||
Tangible Book Value, 3 Yr. CAGR % | 0.07 | 3.01 | 7.21 | 7.79 | 9.27 | |||||
Common Equity, 3 Yr. CAGR % | 2.74 | 5.08 | 6.5 | 6.52 | 8.34 | |||||
Cash From Operations, 3 Yr. CAGR % | 50.41 | 41.46 | 12.93 | 11.3 | -3.77 | |||||
Capital Expenditures, 3 Yr. CAGR % | 10.15 | -8.59 | 1.41 | -10.38 | -11.06 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -33.68 | 9.91 | 9.43 | 22.26 | -20.09 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -55.67 | 31.82 | 6.99 | 142.72 | -13.94 | |||||
Dividend Per Share, 3 Yr. CAGR % | 70.94 | 44.18 | - | 1.42 | 21.5 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 17.46 | 14.74 | 13.69 | 11.5 | 8.82 | |||||
Gross Profit, 5 Yr. CAGR % | 21.46 | 15.26 | 11.84 | 9.9 | 6.24 | |||||
EBITDA, 5 Yr. CAGR % | 22.19 | 12.81 | 11.46 | 11.1 | 4.39 | |||||
EBITA, 5 Yr. CAGR % | 23.01 | 12.67 | 11.35 | 11.21 | 3.72 | |||||
EBIT, 5 Yr. CAGR % | 23.03 | 12.68 | 11.41 | 11.35 | 4 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 36.9 | 23.6 | 9.18 | 10.63 | 9.36 | |||||
Net Income, 5 Yr. CAGR % | 34.66 | 22.8 | 7.6 | 10.15 | 7.75 | |||||
Normalized Net Income, 5 Yr. CAGR % | 22.7 | 12.8 | 10.49 | 11.94 | 11.64 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 29.23 | 18.65 | 4.71 | 9.77 | 9.88 | |||||
Accounts Receivable, 5 Yr. CAGR % | 26.46 | 20.18 | 14.1 | 5.86 | 5.28 | |||||
Inventory, 5 Yr. CAGR % | 12.73 | 8.86 | 7.16 | 7.68 | 10.18 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 15.91 | 14.12 | 10.32 | 8.26 | 6.66 | |||||
Total Assets, 5 Yr. CAGR % | 19.92 | 17.28 | 12.13 | 6.83 | 7.55 | |||||
Tangible Book Value, 5 Yr. CAGR % | 15.22 | 12.91 | 3.29 | 4.57 | 8.46 | |||||
Common Equity, 5 Yr. CAGR % | 16.23 | 13.7 | 4.36 | 5.37 | 7.75 | |||||
Cash From Operations, 5 Yr. CAGR % | 51.19 | 51.65 | 31.54 | 31.18 | 2.18 | |||||
Capital Expenditures, 5 Yr. CAGR % | 7.62 | 3.8 | 2.66 | -10.39 | -3.93 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -10.68 | 14.96 | -0.78 | -6.63 | -8.44 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -28.57 | 29.58 | 7.55 | 8.68 | -5.67 | |||||
Dividend Per Share, 5 Yr. CAGR % | 30.92 | - | 37.94 | 39.11 | - |
Select your edition
All financial news and data tailored to specific country editions